Phase 2

Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).

A first patients has been dosed in the WIN-B study (NCT06612203)*, a Phase 1b/2, multi-center investigator-initiated trial evaluating the safety and preliminary efficacy of...

German-based Tubulis continues the expansion of its clinical pipeline with a second ADC drug candidate entering the clinic. Earlier this week the company announced the dosing of the first patient in the 5-STAR-1-01 clinical trial evaluating ADC candidate TUB-030 in solid tumors.

wo clinical trials testing the antibody loncastuximab tesirine (Zynlonta® ADC Therapeutics) showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

AstraZeneca and Daiichi Sankyo Submit New BLA for Accelerated Approval of Datopotamab Deruxtecan in advanced EGFR-mutated NSCLC

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V/ABBV-399; See Drugmap) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.

During the upcoming annual meeting of the European Society for Medical Oncology (ESMO), being held in Barcelona, September 13-17, 2024, expect presentations to include new data on advances in the treatment of hard-to-treat cancers using approved and investigational agents, including enfortumab vedotin (Padcev™; Astellas/Pfizer/Seagen), Zolbetuximab (previously known as IMAB362), Enzalutamide (Xtandi®; Astellas/Pfizer) and various pipeline products.

During the upcoming European Society for Medical Oncology (ESMO) Congress being held in Barcelona, September 13-17, 2024, expect presentations to include new data on...

Clinical Study finds ADCs to be Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer

At the recently held annual meeting of the American Association for Cancer Research (AACR), positive Phase 2 trial (NCT03835819) results of the combination of mirvetuximab soravtansine and the immune checkpoint inhibitor (ICI) Pembrolizumab (Keytruda®; Merck & Co) in the treatment of folate receptor-alpha (FR-α) positive recurrent microsatellite stable / mismatch repair proficient serous endometrial cancer were presented.